Bausch + Lomb (BLCO) Competitors

Zimmer Biomet (NYSE:ZBH) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, community ranking, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Do analysts rate ZBH or BLCO?

Zimmer Biomet presently has a consensus target price of $124.11, suggesting a potential upside of 13.48%. Bausch + Lomb has a consensus target price of $20.25, suggesting a potential upside of 16.77%. Given Bausch + Lomb's stronger consensus rating and higher probable upside, analysts clearly believe Bausch + Lomb is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2 Sell rating(s)	11 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.29
Bausch + Lomb	1 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.31

Which has better earnings and valuation, ZBH or BLCO?

Zimmer Biomet has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$7.39B	2.94	$1.02B	$5.26	20.79
Bausch + Lomb	$4.15B	1.47	-$260M	-$1.05	-16.52

Is ZBH or BLCO more profitable?

Zimmer Biomet has a net margin of 14.27% compared to Bausch + Lomb's net margin of -7.86%. Zimmer Biomet's return on equity of 12.95% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	14.27%	12.95%	7.55%
Bausch + Lomb	-7.86%	3.17%	1.59%

Do insiders & institutionals have more ownership in ZBH or BLCO?

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 1.0% of Zimmer Biomet shares are owned by insiders. Comparatively, 0.2% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the media prefer ZBH or BLCO?

In the previous week, Zimmer Biomet had 12 more articles in the media than Bausch + Lomb. MarketBeat recorded 23 mentions for Zimmer Biomet and 11 mentions for Bausch + Lomb. Zimmer Biomet's average media sentiment score of 0.72 beat Bausch + Lomb's score of -0.15 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	9 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor ZBH or BLCO?

Zimmer Biomet received 865 more outperform votes than Bausch + Lomb when rated by MarketBeat users. Likewise, 67.14% of users gave Zimmer Biomet an outperform vote while only 41.86% of users gave Bausch + Lomb an outperform vote.

Company	Underperform	Outperform
Zimmer Biomet	Outperform Votes 901 67.14%	Underperform Votes 441 32.86%
Bausch + Lomb	Outperform Votes 36 41.86%	Underperform Votes 50 58.14%

Which has more volatility and risk, ZBH or BLCO?

Zimmer Biomet has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.

Summary

Zimmer Biomet beats Bausch + Lomb on 15 of the 17 factors compared between the two stocks.